About ACD Bio
ACD Bio is a company based in Newark (United States) founded in 2006 was acquired by Bio-Techne in July 2016. ACD Bio has raised $39.4 million across 8 funding rounds from investors including New Leaf Venture Partners, Bio-Techne and HHS. ACD Bio offers products and services including RNAscope Assay, BaseScope Assay, and miRNAscope Assay. ACD Bio operates in a competitive market with competitors including Abcam, Sino Biological, GenScript, Stem Cell Technologies and Miltenyi Biotec, among others.
- Headquarter Newark, United States
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Advanced Cell Diagnostics, Inc.
-
Annual Revenue
$576.82 K (USD)-41as on Dec 31, 2020
-
Net Profit
-$264.49 K (USD)-3889as on Dec 31, 2022
-
EBITDA
Not available
-
Total Equity Funding
$39.4 M (USD)
in 8 rounds
-
Latest Funding Round
$22 M (USD), Series C
Jun 18, 2015
-
Investors
New Leaf Venture Partners
& 7 more
-
Employee Count
Not available
-
Acquired by
Bio-Techne
(Jul 06, 2016)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of ACD Bio
ACD Bio offers a comprehensive portfolio of products and services, including RNAscope Assay, BaseScope Assay, and miRNAscope Assay.
Enables visualization of single RNA molecules in tissues.
Detects RNA targets with high sensitivity in research samples.
Facilitates microRNA detection for gene regulation studies.
Funding Insights of ACD Bio
ACD Bio has successfully raised a total of $39.4M across 8 strategic funding rounds. The most recent funding activity was a Series C round of $22 million completed in June 2015. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in ACD Bio
ACD Bio has secured backing from 8 investors, including venture fund and institutional investors. Prominent investors backing the company include New Leaf Venture Partners, Bio-Techne and HHS.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Stage-agnostic investments in US life sciences are managed.
|
Locked | Locked | Locked | |
|
-
|
Locked | Locked | Locked | |
|
Summit Partners is recognized as a growth equity investment firm.
|
Locked | Locked | Locked |
Investor details for ACD Bio
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by ACD Bio
Investment portfolio details for ACD Bio
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - ACD Bio
Detailed financials for ACD Bio
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Acd Bio Comparisons
Peer comparison for ACD Bio
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of ACD Bio
ACD Bio operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Abcam, Sino Biological, GenScript, Stem Cell Technologies and Miltenyi Biotec, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Biological reagents and antibodies are developed for life science research.
|
|
| Locked | Locked | Locked |
Reagents and kits are provided for clinical research applications.
|
|
| Locked | Locked | Locked |
Reagents and instruments are provided for life sciences research.
|
|
| Locked | Locked | Locked |
Developer of cell culture media and ancillary reagents for life science research
|
|
| Locked | Locked | Locked |
Develops tools and products for research and clinical application
|
|
| Locked | Locked | Locked |
Provider of molecular diagnostic kits for cancer, hereditary diseases, and reproductive disorders
|
Detailed competitors of ACD Bio
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Acd Bio
Complete news archive for ACD Bio
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about ACD Bio
ACD Bio was founded in 2006.
ACD Bio is headquartered in Newark, United States. It is registered at Newark, New Jersey, United States.
ACD Bio is a funded company, having raised a total of $39.4M across 8 funding rounds to date.
Annual revenue of ACD Bio is $576.82K as on Dec 31, 2020.
Founded in 2006 and based in Newark, United States, operations focus on biotechnology for biomarker analysis. A proprietary RNAscope technology is utilized to detect and quantify RNA biomarkers at single-molecule sensitivity in situ. Clinical-grade assay development and biomarker validation services are offered, along with companion diagnostic support. Targeted therapies for cancer and other diseases are facilitated through the platform, which encompasses RNAscope probes, reagent kits, hybridization systems, and software.
ACD Bio's top competitors include Abcam, Sino Biological and Meridian Bioscience.
ACD Bio offers RNAscope Assay, BaseScope Assay, and miRNAscope Assay.
ACD Bio has 8 investors. Key investors include New Leaf Venture Partners, Bio-Techne, HHS, National Cancer Institute, and Kenson Ventures.